TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females age 18-70~* The active arm (Arm #1) includes randomly selected 100-125 charts of patients with a primary diagnosis of major depression and a CGI-S of ≥4 who began Deplin and SSRI or SNRI therapy at the same time beginning in January 2007 to the present; and, Control group (Arm #2) includes randomly selected 125-150 charts of patients with a primary diagnosis of major depression who began SSRI or SNRI therapy matched in severity (CGI-S of ≥4)~Exclusion Criteria:~* Folic acid \>400 mcg taken at any time during the study~* Psychotic features in the current episode or a history of psychotic features~* Any bipolar disorder (current or past) or any psychotic disorder (current or past)~* Current or past treatment with vagus nerve stimulation, ECT, or transcranial magnetic stimulation~* Antipsychotic therapy in conjunction with their antidepressant currently or in past 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Deplin + antidepressant (Type: None): Deplin in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)
- Antidepressant alone (Type: None): SSRI or SNRI alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of FYU-981 in Hyperuricemia With or Without Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperuricemic or gout patients~* Serum urate level:~\>= 7.0mg/dL in patients with history of gout, or \>= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL~Exclusion Criteria:~* Gouty arthritis within two weeks before start of study treatment~* Secondary hyperuricemia~* HbA1c: \>= 8.4%~* Uric acid-overproduction type in the classification of hyperuricemia~* History of, clinically significant cardiac, hematologic and hepatic disease~* Kidney calculi or clinically significant urinary calculi~* eGFR: \< 60mL/min/1.73m\^2~* Systolic blood pressure: \>= 180 mmHg~* Diastolic blood pressure: \>= 110 mmHg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- FYU-981 High dose (Type: ACTIVE_COMPARATOR): None
- FYU-981 Middle dose (Type: ACTIVE_COMPARATOR): None
- FYU-981 Low dose (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic insomnia defined as a) sleep onset latency and/or wake after sleep onset longer than 30 minutes per night, at least 3 nights per week; and b) Insomnia duration of at least 6 months, by self-report; and c) minimum of 1 daytime complaint by self-report (e.g. fatigue, mood disturbance);~* Between 18 and 65 years of age;~* English-speaking;~* Literate;~* Mentally intact;~* Interested in either medication or mind-body interventions;~* Able to attend weekly classes in a Minnesota Metro area;~* Able to comply with study sleep monitoring requirements;~* Willing to complete the informed consent process.~Exclusion Criteria:~* Sleep apnea or other primary sleep disorder suspected of being responsible for insomnia;~* Mental disorder or substance (including medications) suspected of being responsible for insomnia;~* General medical condition suspected of being responsible for the insomnia;~* Medically unstable (a hospital admission for non-elective purposes in the last 3 months or major surgery planned in the next 3 months);~* Serious preexisting mental health issues: suicidality or thought disorder/psychosis; or delirium or substance abuse;~* Treatment for depression or anxiety with initiation of therapy or dosage change within the last 6 months;~* Use of non-prescription sleep aids and unwilling or unable to discontinue these during the study;~* Use of prescription sleep medications or other medications known to affect sleep or be contraindicated with use of hypnotics, and unwilling or unable to discontinue these during the study;~* Known allergy to eszopiclone;~* Shift worker;~* Pregnant , breast-feeding or planning pregnancy in next 6 months;~* Previous cognitive behavioral therapy for insomnia or current psychotherapy;~* Prior MBSR class or regularly practicing mindfulness meditation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MBSR (Type: EXPERIMENTAL): A Mindfulness-Based Stress Reduction (MBSR) program that includes 8-weeks of group instruction in mindfulness meditation techniques followed by home practice and monitoring.
- PCT Sleeping Pills (Type: ACTIVE_COMPARATOR): A pharmacotherapy control arm (PCT Sleeping Pills) consisting of a state-of-the-art prescription sedative hypnotic, eszopiclone - brand name LUNESTA(R), at a dose of one 3 milligram (mg) pill nightly for a duration of 8 weeks followed by use as needed (same dosage) for 3 months. This drug was approved by the Food and Drug Administration as a sedative for more than short term use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Volunteers must be non-smokers for at least 6 months before first study drug administration~* Volunteers must consume no more than 4 to 5 cups of coffee or tea or 8 cans of cola each day~Exclusion Criteria:~* History of or currently active illness considered to be clinically significant by the Investigator or any other illness that the Investigator considers should exclude the patient from the study or that could interfere with the interpretation of the study results~* Female volunteer is breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Sequence 1: Treatment A-B-C (Type: EXPERIMENTAL): The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
- Sequence 2: Treatment B-C-A (Type: EXPERIMENTAL): The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
- Sequence 3: Treatment C-A-B (Type: EXPERIMENTAL): The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Using Multimedia Patient Feedback to Reduce Disparities in VA Healthcare

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Any patient included in the regular panel of a participating physician at either study site who is a returning patient for that physician. Since 2 of the patient perceptual measures included require the pre-existence of a relationship with a specific physician, we will only enroll patients who have been seen by their physician before.~Exclusion Criteria:~* Physical disabilities that prohibit unassisted participation in research protocol:~  * legal blindness~ * dementia~ * severe post-traumatic stress disorder~ * schizophrenic disorder~ * Alzheimer's disease~ * bipolar disorder~ * and severe anxiety and/or mood disorders (must be documented in patient's medical record or attested to by patient, physician or charge nurse).~* Also, no patients new to VA primary care or to a given participating physician will be enrolled.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Provider Communication Skills Training (Type: OTHER): Provider clinical communication training intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multihance at 3 Tesla (3T) in Brain Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Was 18 years or older~* Provided written informed consent~* Scheduled for MRI~* Confirmed or highly suspected to have brain tumor(s) and willing to undergo two MRI exams within 14 days~Exclusion Criteria:~* Pregnant or lactating females~* Allergy to one or more of the ingredients in the products or hypersensitivity to any metals~* Congestive heart failure, class IV~* Previous stroke in the past year~* Received another contrast agent within 24 hours pre and post each exam~* Investigational product~* Contraindications to MRI~* Severe claustrophobia~* Surgery with 3 weeks prior~* Steroid therapy or radiosurgery between two exams

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MultiHance (Type: ACTIVE_COMPARATOR): 0.5 M MultiHance at a single injection
- Magnevist (Type: ACTIVE_COMPARATOR): 0.5 M Magnevist at a single injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Advance Planning for Home Services for Seniors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 65 and older~* English speaking~* Score ≥ 4 questions correctly on the Brief Cognitive screener~* Self-identified comfort using a computer~* Self-identified comfort using the Internet to navigate a Website~* Have not previously participated in study's focus groups or pilot study~Exclusion Criteria:~* Less than age 65~* Non-English speaking~* Score \< 4 questions correctly on the Brief Cognitive screener~* Not comfortable using a computer~* Not comfortable using the Internet to navigate a Website~* Previous participation in this study's focus groups or pilot study

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Plan Your Lifespan Website (Type: EXPERIMENTAL): Participants in the intervention arm will navigate the Plan Your Lifespan website, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. The Plan Your Lifespan tool is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
- Go4Life Website (Type: OTHER): Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. Our attention control group will control for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention website.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects ages 21 to 70 inclusive. Female subjects must be of non-childbearing potential;~* Has at the screening visit a serum uric acid ≥ 6 mg/dL, with or without a history of gout;~* The use of allopurinol, febuxostat (Uloric®), or probenecid as uric acid-lowering therapy is permissible if dosing has been stable for at least the month prior to the screening visit;~* Has adequate venous access and able to receive IV therapy;~* Evidence of a personally signed and dated informed consent document indicating that subject has been informed of all pertinent aspects of the study;~Exclusion Criteria:~* Prior exposure to any experimental or marketed uricase (for arms receiving SEL-037 or SEL-212);~* History of any allergy to pegylated products;~* Glucose-6-phosphate dehydrogenase deficiency or known catalase deficiency;~* History of hematological or autoimmune disorders, is immunosuppressed or immunocompromised;~* Presently taking a drug classified as CYP3A4 inducer or inhibitor;~* Has participated in a clinical trial within 30 days of the Screening;

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SEL-110 (Type: EXPERIMENTAL): Single intravenous dose of SEL-110
- SEL-212 (Type: EXPERIMENTAL): Single intravenous dose of SEL-110 plus SEL-037 (pegsiticase)
- SEL-037 (Type: EXPERIMENTAL): Single intravenous dose of SEL-037 (pegsiticase)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented acute hepatitis C infection with detectable HCV-RNA (PCR-assay) and elevated serum alanine transferase (ALT) levels. An acute infection is defined by fulfilling two of the following 3 criteria within the preceding four months:~  1. known or suspected exposure to HCV,~ 2. documented seroconversion to positivity for antibodies against HCV,~ 3. a serum alanine transferase (ALT) level of more than 350 U/l with a documented normal level during the year before infection.~* Documented HIV-infection~* CD4 cells \> 300 /µl~* Ability to understand and sign a written consent form~* Women of child-bearing age: negative pregnancy test~Exclusion Criteria:~* Autoimmune hepatitis or other autoimmune disease~* Decompensated liver disease~* Decompensated renal disease, i.e. creatinine clearance \< 50 ml/min, according to Cockcroft-Gault~* Acute or chronic hepatitis B infection~* Acute infection with hepatitis A or other hepatotropic viruses~* New AIDS defining event less than 1 month prior to enrolment~* Malignancy other than cutaneous kaposi sarcoma treated with systemic chemo-therapy~* History of severe psychiatric conditions, in particular severe depression~* History of seizures~* History of organ transplantation~* Thyroid disease not medically compensable~* Severe heart disease~* Severe retinopathy~* Known allergy to the study drug or one of the galenic compounds~* Hypersensitivity to interferon a~* Thrombocytes \< 90 G/l, neutrophils \< 1.5 G/l, hemoglobin must not be \< 12g/dl (female) or \< 13 g/dl (male)~* Treatment with corticosteroids less than 3 months prior to enrolment~* Alcohol abuse or use of other recreational drugs~* Older than 65 years of age, younger than 18 years of age~* Pregnancy, breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* written informed consent~* males and non-pregnant, non-lactating females~* BMI 19.0-32.0~* willing to abide by contraceptive requirements~* normal vitals~* willing to abide by study procedures and restrictions~Exclusion Criteria:~* clinically significant medical condition or medical history or psychiatric condition or history of psychiatric condition~* abnormal cardiac finding, or laboratory/urinalysis abnormality at screening~* known family history of sudden death or long QT syndrome, family or personal history of QT prolongation, or arrhythmia that required medical intervention~* current participation in any other investigational drug study or participation in an investigational drug study within 3 months of screening visit~* use of prescription, OTC, or herbal medications during study or use of any specified medications within 30 days prior to study~* Recent or current history of alcohol or drug abuse~* Regular use of tobacco or nicotine products~* Positive serology for HBV, HCV, or HIV~* history of severe adverse reaction to or known sensitivity to any drug~* pregnant, lactating, or planning to become pregnant within 30 days of the study. Male subjects with pregnant female partners are excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Galidesivir (Type: EXPERIMENTAL): Galidesivir IV infusion
- placebo (Type: PLACEBO_COMPARATOR): Placebo IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* IgE-mediated peanut allergy, confirmed at double-blind placebo-controlled food challenge~* Tolerant to at least 1/4 boiled peanut (boiled for 4 hours) at open food challenge.~* Informed consent of parent/legal guardian and patient assent~Exclusion Criteria:~* Allergic to 1/4 boiled peanut at PCFC~* Tolerates ≥1.4 g roasted peanut protein at entry PCFC~* Unstable asthma~* Unwilling or unable to fulfil study requirements~* Undergoing other forms of immunotherapy (e.g. SCIT or SLIT to aeroallergens)~* Previous admission to ICU for management of allergic reaction to peanut~* Clinically significant chronic illness (other than asthma, rhinitis or eczema).~* Undergoing subcutaneous or sublingual immunotherapy and within the first year of therapy, for respiratory allergy.~* Subjects receiving anti-IgE therapy, oral immunosupressants, beta-blocker or ACE inhibitor therapy.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Desensitisation to peanut (Type: EXPERIMENTAL): Desensitisation using boiled peanut
- Control (Type: EXPERIMENTAL): Subjects allocated to the control group will undergo routine care for 12 months, following which they will be offered the active treatment with boiled peanut (as a one-way cross-over intervention).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete